Drugs / Bisthianostat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03618602 | Apr 2018 → Apr 2020 | plasma cell myeloma | Shanghai Theorion Pharmaceutical Co Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bisthianostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03618602 ↗ |
| Action | Inhibit | “Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.” NCT03618602 ↗ |
| Modality | Small molecule | — CHEMBL3287255 ↗ |
| Route | Oral | “100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).” NCT03618602 ↗ |